Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Speculating in Takeover Targets -- Ignore unavailable to you. Want to Upgrade?

To: richardred who wrote (2066)	11/1/2010 9:57:28 AM
From: richardred	Respond to of 7259

McKesson to acquire US Oncology in $2.16B deal McKesson to buy US Oncology in $2.16 billion deal that includes privately held company's debt On Monday November 1, 2010, 8:33 am EDT SAN FRANCISCO (AP) -- McKesson Corp. said Monday it will acquire US Oncology in an all-cash deal it valued at $2.16 billion. McKesson, a San Francisco medical company that specializes in pharmaceutical supplies, said it will buy all the outstanding shares of US Oncology. The deal includes US Oncology's outstanding debt, which McKesson said will be repaid or refinanced. US Oncology is a privately held company based in The Woodlands, Texas. It is affiliated with more than 1,300 oncologists and works with the health care industry in cancer research. McKesson said the move would increase its reach into the growing cancer-treatment industry. "McKesson and US Oncology's businesses are highly complementary, providing our collective customers access to more services and solutions that will enhance their ability to deliver advanced cancer care," Paul Julian, McKesson executive vice president and group president, said in a statement. Bruce Broussard, US Oncology's chairman and CEO, will lead McKesson's specialty care solutions business. He will report to Julian. US Oncology will continue to operate under its brand name. finance.yahoo.com